Soleno Therapeutics Inc (SLNO)

Jun 06, 2025

Soleno Therapeutics Holds Annual Stockholders Meeting - TipRanks

Jun 06, 2025

Jun 05, 2025

Transcript : Soleno Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com

Jun 05, 2025

Jun 04, 2025

Trading (SLNO) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 04, 2025

May 27, 2025

Soleno Therapeutics’ SWOT analysis: vykat xr launch propels stock amid rare disease market potential - Investing.com India

May 27, 2025

May 27, 2025

Stifel maintains Soleno Therapeutics stock Buy rating, $108 target - Investing.com

May 27, 2025

May 27, 2025

Stifel maintains Soleno Therapeutics stock Buy rating, $108 target By Investing.com - Investing.com India

May 27, 2025

May 26, 2025

EMA validates Soleno’s application for Prader-Willi syndrome treatment - Yahoo Finance

May 26, 2025

May 25, 2025

(SLNO) Trading Report - news.stocktradersdaily.com

May 25, 2025

May 23, 2025

Soleno Therapeutics seeking regulatory approval in treatment of PWS - Yahoo Finance

May 23, 2025

May 23, 2025

Sector Update: Health Care Stocks Flat to Lower Pre-Bell Friday - marketscreener.com

May 23, 2025

May 23, 2025

Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock By Investing.com - Investing.com South Africa

May 23, 2025

May 23, 2025

Soleno Application for Hyperphagia Treatment in Patients with Prader-Willi Syndrome Gets European Validation - marketscreener.com

May 23, 2025

May 23, 2025

Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR - Insider Monkey

May 23, 2025

May 23, 2025

Soleno seeks EU approval for Prader-Willi syndrome treatment - Investing.com Australia

May 23, 2025

May 22, 2025

Soleno seeks EU approval for Prader-Willi syndrome treatment By Investing.com - Investing.com Canada

May 22, 2025

May 22, 2025

Soleno Therapeutics' (SLNO) MAA for PWS Treatment Validated by EMA | SLNO Stock News - GuruFocus

May 22, 2025

May 22, 2025

Soleno Therapeutics Announces Submission and EMA Validation - GlobeNewswire

May 22, 2025

May 22, 2025

Soleno's PWS Drug VYKAT Advances in Europe After Recent FDA ApprovalKey Details for Investors - Stock Titan

May 22, 2025

May 22, 2025

BCE Inc: Stock Forecast & Analysis - The Globe and Mail

May 22, 2025

May 22, 2025

Buy AT&T or Verizon Stock if Market Volatility Resurges? - The Globe and Mail

May 22, 2025

May 22, 2025

Cantor Fitzgerald maintains Overweight on Soleno Therapeutics stock - Investing.com Australia

May 22, 2025

May 21, 2025

Soleno Therapeutics to Participate in Upcoming June Conferences - GlobeNewswire

May 21, 2025

May 21, 2025

Lowe’s Stock Uptrend Can Continue for These 2 Reasons - The Globe and Mail

May 21, 2025

May 21, 2025

Rare Disease Leader Soleno Therapeutics Secures Speaking Slots at Major Healthcare Conferences - Stock Titan

May 21, 2025

May 21, 2025

Piper Sandler maintains $145 target on Soleno Therapeutics stock - Investing.com Australia

May 21, 2025

May 20, 2025

Soleno reports positive VYKAT XR results for Prader-Willi syndrome By Investing.com - Investing.com South Africa

May 20, 2025

May 20, 2025

Piper Sandler maintains $145 target on Soleno Therapeutics stock By Investing.com - Investing.com Canada

May 20, 2025

May 20, 2025

Soleno reports positive VYKAT XR results for Prader-Willi syndrome - Investing.com Australia

May 20, 2025

May 20, 2025

Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Resu - GuruFocus

May 20, 2025

May 20, 2025

Soleno Therapeutics (SLNO) Reports Promising Vykat XR Study Results | SLNO Stock News - GuruFocus

May 20, 2025

May 20, 2025

Soleno Therapeutics Presents Positive Clinical Data for VYKAT™ XR at the 2025 Pediatric Endocrine Society Annual Meeting - Nasdaq

May 20, 2025

May 20, 2025

Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants wi - The Manila Times

May 20, 2025

May 20, 2025

VYKAT XR Clinical Data Shows Major Improvements in Prader-Willi Syndrome Symptoms | SLNO Stock News - Stock Titan

May 20, 2025

May 20, 2025

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 20, 2025

May 19, 2025

Company News for May 19, 2025 - The Globe and Mail

May 19, 2025

May 18, 2025

Northern Trust Corp Buys 34,309 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World

May 18, 2025

May 15, 2025

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 - GlobeNewswire

May 15, 2025

May 15, 2025

New Clinical Data Shows VYKAT XR Improves Body Mass and Behavior in Prader-Willi Syndrome Patients - Stock Titan

May 15, 2025

May 13, 2025

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - GlobeNewswire

May 13, 2025

May 12, 2025

SLNO FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World

May 12, 2025

May 11, 2025

Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now? - Insider Monkey

May 11, 2025

May 11, 2025

11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey

May 11, 2025

May 10, 2025

Got $3,000? 2 Artificial Intelligence (AI) Stocks to Buy and Hold for the Long Term - The Globe and Mail

May 10, 2025